New Research Explores on Bile Duct Cancer - Pipeline Review, H2 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.
Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.
Report Highlights
This report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Complete report available @ Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016
The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 49, 18, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.Bile Duct Cancer (Cholangiocarcinoma).
Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)
- The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG Adgero Biopharmaceuticals Inc Agios Pharmaceuticals Inc Ariad Pharmaceuticals Inc ArQule Inc Array BioPharma Inc Arrien Pharmaceuticals LLC Aslan Pharmaceuticals Pte Ltd Bavarian Nordic A/S Bayer AG BeiGene Ltd Blueprint Medicines Corp Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Celgene Corp CellAct Pharma GmbH Cellceutix Corp Cellular Biomedicine Group Inc Concordia International Corp Cornerstone Pharmaceuticals Inc Daiichi Sankyo Company Ltd Delcath Systems Inc Eisai Co Ltd Eli Lilly and Company Exelixis Inc F. Hoffmann-La Roche Ltd H3 Biomedicine Inc Halozyme Therapeutics Inc Hutchison MediPharma Ltd Incyte Corp Innopharmax Inc INSYS Therapeutics Inc Johnson & Johnson Komipharm International Co Ltd Loxo Oncology, Inc. Mebiopharm Co Ltd MedImmune LLC Merck & Co Inc NanoCarrier Co Ltd NormOxys Inc Novartis AG NuCana BioMed Ltd Oasmia Pharmaceutical AB OncoTherapy Science Inc Ono Pharmaceutical Co Ltd Panacea Pharmaceuticals Inc PCI Biotech Holding ASA Pfizer Inc Pharma Mar SA Provecs Medical GmbH Puma Biotechnology Inc RedHill Biopharma Ltd Sanofi Senhwa Biosciences Inc Shanghai Pharmaceutical Co Ltd Sun Pharma Advanced Research Company Ltd SynCore Biotechnology Co Ltd SyntheX Inc Taiwan Liposome Company Ltd tella Inc Threshold Pharmaceuticals Inc VasGene Therapeutics Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 05:54
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home